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Kaposi's sarcoma herpesvirus (KSHV)-infected primary
effusion lymphoma (PEL) typically presents as a malig-
nant effusion in body cavities that disseminates to distant
sites. There is a need for new therapies for PEL as most
patients rapidly succumb in spite of high-dose chemo-
therapy. We examined the potential utility of Rapamycin
for PEL treatment. We found that the downstream effec-
tors of the mammalian target of Rapamycin (mTOR)
p70S6k and S6 are constitutively phosphorylated in PEL
cells, and that Rapamycin inhibits this constitutive
p70S6k and S6 phosphorylation. Rapamycin reduces PEL
proliferation but is not cytotoxic for PEL cells. Intraperito-
neal injection of PEL cells in NOD/SCID mice causes
experimental effusion lymphoma. Rapamycin delayed
PEL development in this model, markedly reduced accu-
mulation of ascites (p = 0.009), prevented formation of
solid tumor masses, and a significantly extended mouse
survival (P < 0.001). However, Rapamycin did not eradi-
cate PEL in mice. We examined the mechanisms by which
Rapamycin reduces PEL progression in this mouse model.
Levels of VEGF, which promotes vascular permeability
and is critical to the accumulation of body cavity fluids,
were significantly reduced in ascites of Rapamycin-treated
mice compared to controls (p = 0.009). Rapamycin inhib-
ited VEGF-induced phosphorylation of VEGF receptor (R)
2 in endothelial cells and activation of the downstream
effectors of VEGFR2 phosphorylation src and enos
(endothelial nitric oxide synthase). Rapamycin did not
alter KSHV genes transcription in PEL cells, and only
insignificantly reduced levels of IL-10, the principal
growth factor for PEL, in ascites of PEL-bearing mice.
Reduction of VEGF secretion by PEL and impairment of
endothelial cell responses to residual VEGF likely explain
reduced accumulation of ascites in Rapamycin-treated
mice. The failure of Rapamycin to significantly reduce IL-
10 levels in PEL-bearing mice and to promote PEL cell
death likely explain PEL persistence in mice treated with
Rapamycin. The successful use of Rapamycin to reduce
PEL effusion and disease progression by reducing VEGF
secretion and endothelial cell responses to VEGF illus-
trates a novel application of mTOR inhibition that targets
the tumor microenvironment rather than the tumor cells,
and is applicable to the treatment of PEL and other malig-
nancies characterized by ascites accumulation and
increased vascular permeability.
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